Ilkka Liikanen

TitlePostdoctoral Scholar
InstitutionUniversity of California San Diego
DepartmentMolecular Biology
Address9500 Gilman Drive #0377
La Jolla CA 92093
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Taipale K, Tähtinen S, Havunen R, Koski A, Liikanen I, Pakarinen P, Koivisto-Korander R, Kankainen M, Joensuu T, Kanerva A, Hemminki A. Interleukin 8 activity influences the efficacy of adenoviral oncolytic immunotherapy in cancer patients. Oncotarget. 2018 Jan 19; 9(5):6320-6335. PMID: 29464075.
      View in: PubMed
    2. Liikanen I, Tähtinen S, Guse K, Gutmann T, Savola P, Oksanen M, Kanerva A, Hemminki A. Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer. Mol Cancer Ther. 2016 09; 15(9):2259-69. PMID: 27458139.
      View in: PubMed
    3. Taipale K, Liikanen I, Koski A, Heiskanen R, Kanerva A, Hemminki O, Oksanen M, Grönberg-Vähä-Koskela S, Hemminki K, Joensuu T, Hemminki A. Predictive and Prognostic Clinical Variables in Cancer Patients Treated With Adenoviral Oncolytic Immunotherapy. Mol Ther. 2016 08; 24(7):1323-32. PMID: 27039846.
      View in: PubMed
    4. Pihkala JI, Järvelä M, Boldt T, Jokinen E, Liikanen I, Mattila I, Eerola A. Fate of fenestration in children treated with fontan operation. Catheter Cardiovasc Interv. 2016 May; 87(6):E233-9. PMID: 26525305.
      View in: PubMed
    5. Bramante S, Koski A, Liikanen I, Vassilev L, Oksanen M, Siurala M, Heiskanen R, Hakonen T, Joensuu T, Kanerva A, Pesonen S, Hemminki A. Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer. Oncoimmunology. 2016 Feb; 5(2):e1078057. PMID: 27057453.
      View in: PubMed
    6. Taipale K, Liikanen I, Juhila J, Turkki R, Tähtinen S, Kankainen M, Vassilev L, Ristimäki A, Koski A, Kanerva A, Diaconu I, Cerullo V, Vähä-Koskela M, Oksanen M, Linder N, Joensuu T, Lundin J, Hemminki A. Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus. Mol Ther. 2016 Feb; 24(1):175-83. PMID: 26310629; PMCID: PMC4754537 [Available on 02/01/17].
    7. Bramante S, Kaufmann JK, Veckman V, Liikanen I, Nettelbeck DM, Hemminki O, Vassilev L, Cerullo V, Oksanen M, Heiskanen R, Joensuu T, Kanerva A, Pesonen S, Matikainen S, Vähä-Koskela M, Koski A, Hemminki A. Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humans. Int J Cancer. 2015 Oct 01; 137(7):1775-83. PMID: 25821063.
      View in: PubMed
    8. Liikanen I, Koski A, Merisalo-Soikkeli M, Hemminki O, Oksanen M, Kairemo K, Joensuu T, Kanerva A, Hemminki A. Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy. Oncoimmunology. 2015 Mar; 4(3):e989771. PMID: 25949903.
      View in: PubMed
    9. Hemminki O, Parviainen S, Juhila J, Turkki R, Linder N, Lundin J, Kankainen M, Ristimäki A, Koski A, Liikanen I, Oksanen M, Nettelbeck DM, Kairemo K, Partanen K, Joensuu T, Kanerva A, Hemminki A. Immunological data from cancer patients treated with Ad5/3-E2F-?24-GMCSF suggests utility for tumor immunotherapy. Oncotarget. 2015 Feb 28; 6(6):4467-81. PMID: 25714011; PMCID: PMC4414204.
    10. Taipale K, Liikanen I, Juhila J, Karioja-Kallio A, Oksanen M, Turkki R, Linder N, Lundin J, Ristimäki A, Kanerva A, Koski A, Joensuu T, Vähä-Koskela M, Hemminki A. T-cell subsets in peripheral blood and tumors of patients treated with oncolytic adenoviruses. Mol Ther. 2015 05; 23(5):964-973. PMID: 25655312; PMCID: PMC4427873.
    11. Kanerva A, Koski A, Liikanen I, Oksanen M, Joensuu T, Hemminki O, Palmgren J, Hemminki K, Hemminki A. Case-control estimation of the impact of oncolytic adenovirus on the survival of patients with refractory solid tumors. Mol Ther. 2015 Feb; 23(2):321-9. PMID: 25381801; PMCID: PMC4445619.
    12. Bramante S, Koski A, Kipar A, Diaconu I, Liikanen I, Hemminki O, Vassilev L, Parviainen S, Cerullo V, Pesonen SK, Oksanen M, Heiskanen R, Rouvinen-Lagerström N, Merisalo-Soikkeli M, Hakonen T, Joensuu T, Kanerva A, Pesonen S, Hemminki A. Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans. Int J Cancer. 2014 Aug 01; 135(3):720-30. PMID: 24374597.
      View in: PubMed
    13. Hirvinen M, Heiskanen R, Oksanen M, Pesonen S, Liikanen I, Joensuu T, Kanerva A, Cerullo V, Hemminki A. Fc-gamma receptor polymorphisms as predictive and prognostic factors in patients receiving oncolytic adenovirus treatment. J Transl Med. 2013 Aug 21; 11:193. PMID: 23965133; PMCID: PMC3765225.
    14. Liikanen I, Ahtiainen L, Hirvinen ML, Bramante S, Cerullo V, Nokisalmi P, Hemminki O, Diaconu I, Pesonen S, Koski A, Kangasniemi L, Pesonen SK, Oksanen M, Laasonen L, Partanen K, Joensuu T, Zhao F, Kanerva A, Hemminki A. Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients. Mol Ther. 2013 Jun; 21(6):1212-23. PMID: 23546299; PMCID: PMC3681222.
    15. Kanerva A, Nokisalmi P, Diaconu I, Koski A, Cerullo V, Liikanen I, Tähtinen S, Oksanen M, Heiskanen R, Pesonen S, Joensuu T, Alanko T, Partanen K, Laasonen L, Kairemo K, Pesonen S, Kangasniemi L, Hemminki A. Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus. Clin Cancer Res. 2013 May 15; 19(10):2734-44. PMID: 23493351.
      View in: PubMed
    16. Koski A, Raki M, Nokisalmi P, Liikanen I, Kangasniemi L, Joensuu T, Kanerva A, Pesonen S, Alemany R, Hemminki A. Verapamil results in increased blood levels of oncolytic adenovirus in treatment of patients with advanced cancer. Mol Ther. 2012 Jan; 20(1):221-9. PMID: 22044933; PMCID: PMC3255582.
    17. Liikanen I, Monsurrò V, Ahtiainen L, Raki M, Hakkarainen T, Diaconu I, Escutenaire S, Hemminki O, Dias JD, Cerullo V, Kanerva A, Pesonen S, Marzioni D, Colombatti M, Hemminki A. Induction of interferon pathways mediates in vivo resistance to oncolytic adenovirus. Mol Ther. 2011 Oct; 19(10):1858-66. PMID: 21792178; PMCID: PMC3188743.
    18. Liikanen I, Dias JD, Nokisalmi P, Sloniecka M, Kangasniemi L, Rajecki M, Dobner T, Tenhunen M, Kanerva A, Pesonen S, Ahtiainen L, Hemminki A. Adenoviral E4orf3 and E4orf6 proteins, but not E1B55K, increase killing of cancer cells by radiotherapy in vivo. Int J Radiat Oncol Biol Phys. 2010 Nov 15; 78(4):1201-9. PMID: 20832189.
      View in: PubMed
    19. Dias JD, Liikanen I, Guse K, Foloppe J, Sloniecka M, Diaconu I, Rantanen V, Eriksson M, Hakkarainen T, Lusky M, Erbs P, Escutenaire S, Kanerva A, Pesonen S, Cerullo V, Hemminki A. Targeted chemotherapy for head and neck cancer with a chimeric oncolytic adenovirus coding for bifunctional suicide protein FCU1. Clin Cancer Res. 2010 May 01; 16(9):2540-9. PMID: 20388844.
      View in: PubMed
    20. Dias JD, Guse K, Nokisalmi P, Eriksson M, Chen DT, Diaconu I, Tenhunen M, Liikanen I, Grénman R, Savontaus M, Pesonen S, Cerullo V, Hemminki A. Multimodal approach using oncolytic adenovirus, cetuximab, chemotherapy and radiotherapy in HNSCC low passage tumour cell cultures. Eur J Cancer. 2010 Feb; 46(3):625-35. PMID: 20006487.
      View in: PubMed